Novartis Raises Guidance on Profit, Sales Growth — Update
By Helena Smolak
Novartis lifted its full-year guidance after first-quarter profit and sales rose and beat consensus expectations, boosted by strong sales of key drugs.
The Swiss pharmaceutical major said Tuesday that it now projects net sales in 2024 to grow in the high-single to low-double-digit percentage range, after previously guiding for growth in the mid-single-digit range.
Novartis now expects core operating income growth in the low double-digit to mid-teens range, having previously expected high single-digit growth.
At 0730 GMT, Novartis shares rose 4.6% to CHF91.52, their highest percentage growth year to date. The stock fell 2.1% over the past three months.
Its core operating profit--one of its preferred earnings metrics, which strips out exceptional items--rose 16% on year in the first quarter to $4.54 billion, excluding its former generics drugs business Sandoz, which was spun-off last October.
Sales climbed to $11.83 billion from $10.80 billion, excluding Sandoz. Strong growth in sales of the company's Entresto heart drug and Cosentyx psoriasis treatment, which both topped $1 billion in quarterly revenue, helped the top line.
Analysts polled by Visible Alpha had forecast the company's first-quarter core operating profit at $4.245 billion and sales at $11.38 billion.
Sales of its prostate-cancer drug Pluvicto climbed 47% to $310 million in the first quarter due to restored supply chains but missed analysts' expectations of $321.1 million, according to a Visible Alpha-compiled consensus.
Novartis aims to open new production sites for Pluvicto and expects continued sales growth in the U.S. throughout the year and additional growth in Europe in the second half, Chief Financial Officer Harry Kirsch said in a press call.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
April 23, 2024 04:20 ET (08:20 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
3 Dividend Stocks for June 2024
-
After Earnings, Is Alibaba Stock a Buy, Sell, or Fairly Valued?
-
MongoDB Earnings: Slashing Valuation as Execution and Macro to Blame for Lower Guidance
-
Marvell Earnings: We Raise Our Medium-Term AI Forecast and Bring Our Valuation Up to $75
-
Zscaler Earnings: Impressive Traction in Emerging Products Drives Sales Growth for the Quarter
-
Dell Earnings: Raising Valuation on Strong AI, but the Stock Remains Severely Overvalued
-
After Earnings, Is Nvidia Stock a Buy, Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now